Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 25 versus ADHANSIA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 25 versus ADHANSIA XR.
ADDERALL XR 25 vs ADHANSIA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall XR is a combination of dextroamphetamine and amphetamine, which are non-catecholamine sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from presynaptic nerve terminals and inhibit their reuptake, resulting in increased synaptic concentrations. This leads to CNS stimulation.
Adhansia XR is a central nervous system (CNS) stimulant. The mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully known, but it is thought to involve blockade of norepinephrine and dopamine reuptake into presynaptic neurons, increasing their levels in the synaptic cleft. This enhances attention and reduces impulsivity.
20-60 mg orally once daily in the morning; starting dose 20 mg, titrate weekly by 10-20 mg based on response and tolerability.
Methylphenidate hydrochloride extended-release: Oral, 18-72 mg once daily in the morning.
None Documented
None Documented
Dextroamphetamine: 10-13 hours; levoamphetamine: 11-14 hours. Effective half-life supports once-daily dosing with extended duration.
Mean terminal elimination half-life is 7.5 hours (range 5-10 hours) following oral administration, allowing twice-daily dosing.
Renal: approximately 90% (30-40% unchanged, remainder as metabolites); fecal: minimal (<2%) via biliary elimination.
Primarily renal (78% as unchanged drug), with 10% biliary/fecal elimination.
Category C
Category C
CNS Stimulant
CNS Stimulant